Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of tenapanor (KHK7791) in hyperphosphatemia patients on hemodialysis
jRCT2080224557Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tenapanor in hyperphosphatemia and chronic kidney disease (CKD) (4 arms), sponsored by Kyowa Kirin. Primary endpoint: Change in serum phosphorus. Started Feb 2019; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080224557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224557.